Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-04-12 | Amended | $25,510,205 | $13,507,805 | Equity and Debt | 06b | SEC link |
| 2022-06-09 | New | $12,002,400 | $12,002,400 | Equity and Debt | 06b | SEC link |
| 2020-07-22 | New | $20,371,187 | $20,371,187 | Equity Only | 06b | SEC link |
| 2018-06-27 | New | $6,000,000 | $6,000,000 | Equity and Debt | 06b | SEC link |
| 2016-07-05 | New | $13,999,912 | $13,999,912 | Equity Only | 06b | SEC link |
| 2014-05-05 | New | $13,500,000 | $13,500,000 | Equity Only | 06b | SEC link |
| 2012-06-19 | New | $10,650,000 | $10,650,000 | Equity Only | 06 | SEC link |
| Name | Role |
|---|---|
| Troy Alstead | Director |
| Greg Archambeau | Executive |
| Karl Bandlien | Director |
| Tom Bumol | Director |
| Bruce Buskirk | Executive |
| Patrick Caruana | Director |
| Chris Fibiger | Director |
| William Gallacher | Director |
| Liam Gallacher | Director |
| Lee Huntsman | Director |
| Matt Ireland | Director |
| Jim Nordstrom | Director |
| James Nordstrom | Director |
| Marsha Russell | Director |
| Eric Russell | Director |
| Jeffrey Smith | Director |
| Jane Taylor | Director |
| Bert Van Den Bergh | Director |
| Scott Walcheck | Director |
| Scott Walchek | Director |